Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Fineline Cube Jul 9, 2026
Company Deals

Xenovector and Jilin University Launch Strategic Partnership to Advance Gene-Edited Pig Organ Transplantation from Breakthrough to Affordable Healthcare

Fineline Cube Jul 9, 2026
Company Deals

Zhejiang Hisun Pharmaceutical and Tigermed Forge Strategic Alliance to Create End-to-End Innovative Drug Development Pipeline

Fineline Cube Jul 9, 2026
Company Deals

Transcenta Returns Select Lilly Assets in Portfolio Restructuring, Retains Blosozumab Rights

Fineline Cube Jul 8, 2026
Company Deals Digital

Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory

Fineline Cube Jul 8, 2026
Policy / Regulatory

China’s National Health Commission Unveils 2026 Essential Medicines List, Adding 116 New Drugs with Full Insurance Coverage

Fineline Cube Jul 9, 2026
Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Fineline Cube Jul 9, 2026
Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Fineline Cube Jul 9, 2026
Company

EpimAb Biotherapeutics Appoints Dr. Zhu Yonghong as Chief Medical Officer

Fineline Cube Jun 8, 2023

Shanghai-based biotech company EpimAb Biotherapeutics has announced the appointment of Dr. Zhu Yonghong to the...

Company Drug

CStone Pharmaceuticals and Servier Report Positive AGILE Study Results for Tibsovo at ASCO

Fineline Cube Jun 7, 2023

CStone Pharmaceuticals’ (HKG: 2616) French partner, Servier, has published the latest results of the global...

Company Drug

BioNTech’s DB-1303 ADC Shows Promising Results in Solid Tumor Phase I/IIa Trial

Fineline Cube Jun 7, 2023

Germany’s BioNTech (NASDAQ: BNTX) has released preliminary data from a Phase I/IIa trial for DB-1303,...

Company Drug

Gilead’s Kite Announces Breakthrough Phase III Results for Yescarta in r/r LBCL

Fineline Cube Jun 7, 2023

Gilead’s (NASDAQ: GILD) subsidiary Kite has published groundbreaking Phase III results for Yescarta (axicabtagene ciloleucel),...

Company Drug

ITabMed Ltd Receives NMPA IND Approval for A-337, a CD3-Activating BsAb Targeting EpCAM

Fineline Cube Jun 7, 2023

Shanghai-based biotech firm ITabMed Ltd has announced the receipt of Investigational New Drug (IND) approval...

Policy / Regulatory

China’s MOST Issues Updated HGR Rules Impacting Foreign Collaborations in Genetic Research

Fineline Cube Jun 7, 2023

China’s Ministry of Science and Technology (MOST) has issued the “Detailed Implementation Rules for the...

Company Drug

Luye Pharma’s Lurbinectedin for Metastatic SCLC Accepted for Review by China’s NMPA

Fineline Cube Jun 7, 2023

China-based Luye Pharma Group (HKG: 2186) has announced that its market filing for lurbinectedin (LY01017)...

Company Deals Digital

Shanghai Runda Medical Science and Technology Partners with Huawei Cloud on AI in Healthcare

Fineline Cube Jun 7, 2023

China-based Shanghai Runda Medical Science and Technology Co., Ltd (SHA: 603108) is set to collaborate...

Company Drug

Lee’s Pharmaceutical Subsidiary Zhaoke Ophthalmology Announces FDA Review of NVK002 for Pediatric Myopia

Fineline Cube Jun 7, 2023

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has announced...

Company Drug

Legend Biotech Submits sBLA to Expand Carvykti Label for Relapsed Multiple Myeloma

Fineline Cube Jun 7, 2023

Legend Biotech Corporation (NASDAQ: LEGN) has announced the submission of a supplemental Biologics License Application...

Company Medical Device

Zai Lab and Novocure’s TTFields Show Survival Benefit in NSCLC, Despite Stock Plunge

Fineline Cube Jun 7, 2023

China-based Zai Lab Ltd (ZLAB) (NASDAQ: ZLAB; HKG: 9688) and its partner Novocure Ltd (NASDAQ:...

Company Deals

Shanghai Junshi Biosciences to List GDRs on Swiss Exchange, Raising RMB 3.4 Billion

Fineline Cube Jun 6, 2023

China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) is preparing to issue 68,292,200...

Company Drug

CStone Pharmaceuticals Presents Ayvakit Data for Advanced GIST at ASCO 2023

Fineline Cube Jun 6, 2023

China-based CStone Pharmaceuticals (HKG: 2616) announced that new data from a post hoc analysis of...

Company Drug

Hansoh Pharmaceutical Gets NMPA Approval for HS-20117 Bispecific Antibody Clinical Study

Fineline Cube Jun 6, 2023

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced receiving approval from the National...

Company Drug

Chinese Pharma Companies Update Pipelines at ASCO 2023 Annual Meeting

Fineline Cube Jun 6, 2023

A number of Chinese pharmaceutical companies have shared updates on their pipeline developments at the...

Company Deals

Sinovac Biotech Partners with Bogota to Establish BogotáBio for Vaccine Production

Fineline Cube Jun 6, 2023

China-based Sinovac Biotech Ltd (NASDAQ: SVA) has announced a strategic partnership with Bogota, the capital...

Company Deals

Longreach Group Puts Quasar Medical on the Block, Attracting Major Bidders

Fineline Cube Jun 6, 2023

Private equity firm Longreach Group, which specializes in the Asian market, is in the process...

Company Drug

Gracell Biotechnologies’ GC012F Showcases Positive Data at ASCO Annual Meeting

Fineline Cube Jun 6, 2023

Suzhou-based biotech firm Gracell Biotechnologies Inc., (Nasdaq: GRCL) has announced positive data for its pipeline...

Company Drug

Biosyngen’s BRG01 Earns Orphan Drug Designation from US FDA for Nasopharyngeal Carcinoma

Fineline Cube Jun 5, 2023

Biosyngen, a leading cell therapy developer based in Guangzhou, has announced that it has received...

Company Medical Device

NMPA Clears Medtronic’s Corindus for Marketing of Advanced Coronary Surgery Systems

Fineline Cube Jun 5, 2023

The National Medical Products Administration (NMPA) has granted marketing approval for the “coronary artery interventional...

Posts pagination

1 … 544 545 546 … 693

Recent updates

  • Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients
  • Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs
  • Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial
  • Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST
  • Changchun High & New Technology’s Subsidiary GenSci Secures NMPA IND Acceptance for GenSci148, First-in-Class VEGF Multi-Blocker for Retinal Vascular Diseases
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Company Drug

Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.